Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2023-10-27 Regulatory Filings
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter dated October 26, 2023, addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1 filed by Aeglea BioTherapeutics, Inc. The letter responds to SEC staff comments about the company's status as a shell company and discusses the company's operations, assets, and merger activities. It includes legal analysis, references to regulatory rules (Securities Act Rule 145(c), Rule 405), and detailed financial and operational data. The document is not a financial report itself but a regulatory correspondence responding to SEC comments on a registration filing. It does not contain financial statements or earnings data but rather legal and regulatory discussion and company responses to SEC inquiries. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and correspondence that do not fit other categories.
2023-10-27 English
Regulatory Filings 2023
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, documents that do not fit any specific category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of information.
2023-10-24 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 24, 2023, by Aeglea BioTherapeutics, Inc. The key content is the posting of an updated corporate presentation on the company's website, which is furnished as Exhibit 99.1. The text explicitly states that the presentation is a "Corporate Presentation" and includes research program updates. The document is relatively short (3854 characters) and primarily serves to announce the availability of this presentation rather than containing detailed financial statements or analysis. According to the classification rules, such a document announcing or furnishing a presentation for investors fits best under the category of Investor Presentation (IP).
2023-10-24 English
Regulatory Filings 2023
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of identifiable information and the fallback rule for documents that do not neatly fit into any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable for more specific classification.
2023-10-20 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from Aeglea BioTherapeutics, Inc. responding to comments from the SEC Division of Corporation Finance regarding a Registration Statement on Form S-3 filed on August 7, 2023. The letter discusses amendments to the registration statement, specifically changing the filing to Form S-1 as requested by the SEC staff. The content is a regulatory correspondence addressing SEC comments and company responses, not a financial report or earnings release. The document length is 3399 characters, which is relatively short and consistent with a regulatory filing or comment letter rather than a full report. There is no substantive financial data or detailed report content, only a response to regulatory comments. Therefore, this document fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and correspondence with regulators that do not fit other categories.
2023-10-07 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is a Form S-1/A registration statement amendment filed with the SEC, related to securities registration and offering. It includes detailed information about the securities being registered, selling stockholders, and the offering process. It is a regulatory filing related to securities registration under the Securities Act of 1933, not a financial report, earnings release, or other types of corporate filings. The document is lengthy (15,000 characters) and contains detailed prospectus information, but it is not an annual report, audit report, or earnings release. It is a registration statement amendment, which falls under the category of Regulatory Filings (RNS) as it does not fit other specific categories and is a general SEC filing related to compliance and disclosure.
2023-10-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.